CorMedix (NASDAQ: CRMD) reported Q2 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $810 thousand versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.